Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.
Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Hernández-Pérez S, Merino N, Bonet J, Navarro R, Van Bergen En Henegouwen PMP, Lykkemark S, Mikkelsen K, Mølgaard K, Jabs F, Sanz L, Blanco FJ, Roda-Navarro P, Alvarez-Vallina L. Harwood SL, et al. Among authors: van bergen en henegouwen pmp. Oncoimmunology. 2017 Sep 27;7(1):e1377874. doi: 10.1080/2162402X.2017.1377874. eCollection 2017. Oncoimmunology. 2017. PMID: 29296540 Free PMC article.
Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.
Compte M, Harwood SL, Martínez-Torrecuadrada J, Perez-Chacon G, González-García P, Tapia-Galisteo A, Van Bergen En Henegouwen PMP, Sánchez A, Fabregat I, Sanz L, Zapata JM, Alvarez-Vallina L. Compte M, et al. Among authors: van bergen en henegouwen pmp. Front Immunol. 2021 Jan 7;11:614363. doi: 10.3389/fimmu.2020.614363. eCollection 2020. Front Immunol. 2021. PMID: 33488625 Free PMC article.
Bispecific antibody platforms for cancer immunotherapy.
Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, van der Vliet HJ. Lameris R, et al. Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65. doi: 10.1016/j.critrevonc.2014.08.003. Epub 2014 Aug 20. Crit Rev Oncol Hematol. 2014. PMID: 25195094 Review.
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ. de Bruin RCG, et al. Among authors: van der vliet hj, van bergen en henegouwen pmp. Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017. Oncoimmunology. 2017. PMID: 29296532 Free PMC article.
Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen En Henegouwen PM, Storm G, Roovers RC. Oliveira S, et al. J Control Release. 2010 Jul 14;145(2):165-75. doi: 10.1016/j.jconrel.2010.03.020. Epub 2010 Mar 31. J Control Release. 2010. PMID: 20362020
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, Verkleij AJ, van Dongen GA, van Bergen en Henegouwen PM. Roovers RC, et al. Int J Cancer. 2011 Oct 15;129(8):2013-24. doi: 10.1002/ijc.26145. Epub 2011 Aug 8. Int J Cancer. 2011. PMID: 21520037 Free PMC article.
146 results